Literature DB >> 16318431

Gastric and gastro-oesophageal cancer therapy.

Prajnan Das1, Jaffer A Ajani.   

Abstract

Gastric and gastro-oesophageal cancers represent a global health problem. In recent years, there has been a marked increase in the incidence of proximal gastric and distal oesophageal adenocarcinomas. Surgery is the primary therapy for localised gastric or gastro-oesophageal cancer; however, patients treated with surgery have high rates of local and distant relapse as well as an unacceptably low 5-year survival rate. Chemoradiation and preoperative chemotherapy can play an important role for these patients. The outcome of patients with metastatic disease is very poor but a number of newer chemotherapy agents, such as docetaxel, oxaliplatin and S-1, have been identified and some have shown promising results. This article reviews recent trials on localised and metastatic gastric and gastro-oesophageal cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16318431     DOI: 10.1517/14656566.6.16.2805

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

1.  The effect of docetaxel (taxotere) on human gastric cancer cells exhibiting low-dose radiation hypersensitivity.

Authors:  Elizabeth K Balcer-Kubiczek; Mona Attarpour; Jian Z Wang; William F Regine
Journal:  Clin Med Oncol       Date:  2008-03-28

2.  Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis.

Authors:  Bo Li; Lian Chen; Hong-Liang Luo; Feng-Ming Yi; Yi-Ping Wei; Wen-Xiong Zhang
Journal:  World J Clin Cases       Date:  2019-03-06       Impact factor: 1.337

Review 3.  Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis.

Authors:  Xiao-Long Chen; Xin-Zu Chen; Chen Yang; Yan-Biao Liao; He Li; Li Wang; Kun Yang; Ka Li; Jian-Kun Hu; Bo Zhang; Zhi-Xin Chen; Jia-Ping Chen; Zong-Guang Zhou
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.